• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Achaogen awarded $60M contract

Achaogen awarded $60M contract

June 12, 2013
CenterWatch Staff

Achaogen, a biopharmaceutical company focused on discovering, developing and commercializing treatments for serious infections caused by multi-drug resistant gram-negative bacteria, has been awarded a $60 million contract option from the Biomedical Advanced Research and Development Authority (BARDA). The option supports the conduct of a global phase III study to evaluate the efficacy and safety of plazomicin in treating patients with gram-negative bacterial infections due to CRE.

This pathogen-specific study represents a new development approach to address unmet medical needs for multi-drug resistant bacterial infections. The study is expected to start in the fourth quarter.

"The growing prevalence of CRE infections poses a substantial public health threat, given the high mortality rates associated with CRE infections,” said Kenneth J. Hillan, M.B. Ch.B., chief executive officer and chief medical officer of Achaogen.

Plazomicin is a next-generation aminoglycoside antibiotic engineered to overcome aminoglycoside resistance mechanisms. It has bactericidal activity against gram-negative pathogens, including strains resistant to carbapenem antibiotics—a last line of defense against resistant infections. Plazomicin is also being developed for the treatment of infections caused by biothreat agents, including Yersinia pestis, which causes plague, and Francisella tularensis, which causes tularemia.

The option was issued under BARDA's Broad Spectrum Antimicrobials (BSA) program, extending Achaogen's original contract awarded in September of 2010 with initial committed funding of $27 million. In 2012, BARDA exercised an additional $16 million contract option. The new option brings the total value of the contract to $103 million.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing